Great Basin Scientific Inc. (GBSN) 3.90 $GBSN
Great Basin Scientific (GBSN) Stock Surges Today After Patent Issuance
at The Street - Tue Mar 31, 12:56PM CDT
Shares of Great Basin Scientific (GBSN) surged Tuesday after the United States Patent and Trademark Office (USPTO) issued a patent for the company's sample-to-result molecular diagnostic testing technology.
GBSN: 3.90 (+1.46)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Mar 31, 11:45AM CDT
CLNT: 3.06 (-0.39), RADA: 2.90 (+0.31), BDR: 0.96 (-0.76), PNX: 49.99 (-6.08), CLWT: 2.91 (-0.52), OFIX: 35.89 (+4.58), EGY: 2.45 (-0.68), HKTV: 9.57 (+1.97), WTT: 2.60 (-0.40), GV: 1.94 (-0.65), SNTA: 1.94 (-0.39), GBSN: 3.90 (+1.46), CNDO: 3.85 (+0.31), CONN: 30.28 (+1.61), DANG: 9.55 (+1.17), SMTX: 1.48 (+0.21), CBMG: 31.46 (-5.49), MRVC: 7.35 (+0.33), AMCO: 1.14 (-0.16), MOV: 28.52 (+2.89)
Great Basin Sci awarded patent covering molecular test method; shares up 53%
Seeking Alpha - at Seeking Alpha - Tue Mar 31, 11:00AM CDT
GBSN: 3.90 (+1.46)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Tue Mar 31, 8:13AM CDT
GV: 1.94 (-0.65), CANF: 2.23 (+0.03), SNTA: 1.94 (-0.39), BCRX: 9.03 (+0.46), GBSN: 3.90 (+1.46), TCK: 13.73 (-1.54), CHTR: 193.11 (+9.72), DANG: 9.55 (+1.17), CLDN: 18.94 (-2.73), REXX: 3.72 (-0.13), MOV: 28.52 (+2.89)
Great Basin Receives Patents for Company's Sample-to-Result Molecular Diagnostic Testing Technology
PR Newswire - Tue Mar 31, 7:00AM CDT
Great Basin Scientific, Inc. (NASDAQ: GBSN and GBSNU), a molecular diagnostics company, today announced that the United States Patent and Trademark Office (USPTO) issued a notice of allowance for patent 8,936,921 for the Company's method of isothermal helicase-dependent amplification (HDA) using blocked primers (bp), or "bpHDA." bpHDA creates a highly specific "hot-start" functionality which increases the amplification speed, improves assay sensitivity and expands multiplex capabilities of Great Basin's sample-to-result molecular diagnostic testing technology. bpHDA is the basis of the Company's Clostridium difficile (C. diff) molecular diagnostic test assay.
GBSN: 3.90 (+1.46), GBSNU: 13.40 (+2.65)
Great Basin Scientific up almost 50% in early trading
Seeking Alpha - at Seeking Alpha - Fri Mar 27, 9:16AM CDT
GBSN: 3.90 (+1.46)
Great Basin Schedules Conference Call to Provide Update on Corporate Progress
PR Newswire - Mon Mar 16, 3:41PM CDT
Great Basin Scientific, Inc. (NASDAQ: GBSN and GBSNU), a molecular diagnostics company, announced today it will host a management presentation on Wednesday, March 18, 2015 at 4:30 p.m. Eastern Time, to provide an update on Great Basin's progress and development programs.
GBSN: 3.90 (+1.46), GBSNU: 13.40 (+2.65)
Great Basin Scientific, Inc. Announces Initial Closing of Public Offering
PR Newswire - Tue Mar 03, 7:00AM CST
Great Basin Scientific, Inc., (NASDAQ: GBSN and GBSNU), announced today that it has completed an initial closing of a follow-on offering with respect to 2,551,965 units (out of a maximum offering of 2,724,000 units) at $8.80 per Unit for gross proceeds of $22.5 million and net proceeds of $20.5 million. Each unit consists of one share of Series E preferred stock and eight Series C warrants. Each share of Series E preferred stock will be convertible into four shares of common stock and each Series C warrant will be exercisable into one share of common stock at an exercise price of $2.55 per share. The Units will automatically separate into the Series E preferred stock and Series C warrants on August 25, 2015, provided that the Units will separate earlier if at any time after March 27, 2015 the closing price of Great Basin's common stock is greater than $4.00 per share for 20 consecutive trading days. The Units will begin trading on The Nasdaq Capital Market under the ticker symbol "GBSNU" beginning March 3, 2015.
GBSN: 3.90 (+1.46), GBSNU: 13.40 (+2.65)
Great Basin Scientific ups revenues 100% in FY14
Seeking Alpha - at Seeking Alpha - Wed Feb 18, 8:48AM CST
GBSN: 3.90 (+1.46)
Great Basin Scientific reports Q4 results
Seeking Alpha - at Seeking Alpha - Wed Feb 18, 7:36AM CST
GBSN: 3.90 (+1.46)
Great Basin Scientific Announces Fourth Quarter 2014 and Full Year 2014 Financial Results
PR Newswire - Wed Feb 18, 7:00AM CST
Great Basin Scientific, Inc. (NASDAQ: GBSN), a molecular diagnostics company, today reported financial results for the fourth quarter and the full year ended December 31, 2014. For the fourth quarter of 2014, revenue was $445,283, an increase of 50.5% compared to $295,785 for the fourth quarter of 2013. For the 12 months ended December 31, 2014 revenue was $1,606,254, an increase of 111.2% compared to $760,646 for the 12 months ended December 31, 2013.
GBSN: 3.90 (+1.46)
Great Basin begins clinical trial for Shiga toxin-producing E. coli & serotype E. coli O157:H7
M2 - Fri Feb 13, 6:31AM CST
Molecular diagnostics company Great Basin Scientific (NasdaqCM:GBSN) reported on Thursday the start of a clinical trial for its Shiga toxin-producing E. coli (STEC) diagnostic test.
GBSN: 3.90 (+1.46)
Great Basin Initiates Clinical Trial for Shiga Toxin-Producing E. coli Molecular Diagnostic Test
PR Newswire - Thu Feb 12, 7:30AM CST
Great Basin Scientific, Inc. (NASDAQ: GBSN), today announced it has initiated a clinical trial for its Shiga toxin-producing E. coli (STEC) diagnostic test. The Great Basin STEC diagnostic test will also detect serotype E. coli O157:H7.
GBSN: 3.90 (+1.46)
13 IPOs You Wish You Didn't Buy in 2014 (And Killed Your Portfolio)
at The Street - Fri Feb 06, 11:55AM CST
Here are the 13 worst performing IPO stocks in 2014.
ROKA: 3.20 (+0.07), SHAK: 50.05 (+0.43), BRDR: 6.01 (-0.14), ECR: 5.62 (+0.10), BIOC: 2.24 (-0.10), ATEN: 4.33 (+0.04), CRCM: 7.58 (-0.20), AMDA: 0.35 (-0.05), MOLG: 2.29 (+0.06), SGNL: 2.15 (-0.11), GBSN: 3.90 (+1.46), FMSA: 7.24 (+0.05), HELI: 1.33 (+0.08), REPH: 9.07 (+0.03)
Great Basin CEO, Ryan Ashton, to Present at OneMedForum 2015
PR Newswire - Thu Jan 08, 7:30AM CST
Ryan Ashton, co-founder and CEO of Great Basin Scientific, Inc. (NASDAQ: GBSN), a molecular diagnostics company, will speak at 2:20 p.m. PST, Jan. 13, at the 8th Annual OneMedForum 2015 at the Marriott Marquis Hotel in San Francisco. Management will also be available for investor meetings on Jan. 13.
GBSN: 3.90 (+1.46)
Great Basin Appoints New Board Members
PR Newswire - Tue Dec 16, 7:30AM CST
Great Basin Scientific, Inc. (NASDAQ: GBSN), a molecular diagnostics company, today welcomed Ronald K. Labrum and Sam Chawla to its board of directors. The two directors joined the board on Oct. 9 (concurrent with the Company's Initial Public Offering), expanding the size of the Great Basin's board of directors from three to five. Both Mr. Labrum and Mr. Chawla will serve as independent directors at Great Basin Scientific, Inc.
GBSN: 3.90 (+1.46)
Great Basin Schedules Product Roadmap Update Call and Webcast
PR Newswire - Thu Dec 11, 4:29PM CST
Great Basin Scientific, Inc. (NASDAQ: GBSN), a molecular diagnostics company, announced today it will host a management presentation on Wednesday, December 17, 2014 at 4:15 p.m. Eastern Time, to discuss progress on the Company's roadmap.
GBSN: 3.90 (+1.46)
Great Basin Scientific (GBSN) Stock Surges Today After Patent Issuance
at The Street - Tue Mar 31, 12:56PM CDT
Shares of Great Basin Scientific (GBSN) surged Tuesday after the United States Patent and Trademark Office (USPTO) issued a patent for the company's sample-to-result molecular diagnostic testing technology.
GBSN: 3.90 (+1.46)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Mar 31, 11:45AM CDT
CLNT: 3.06 (-0.39), RADA: 2.90 (+0.31), BDR: 0.96 (-0.76), PNX: 49.99 (-6.08), CLWT: 2.91 (-0.52), OFIX: 35.89 (+4.58), EGY: 2.45 (-0.68), HKTV: 9.57 (+1.97), WTT: 2.60 (-0.40), GV: 1.94 (-0.65), SNTA: 1.94 (-0.39), GBSN: 3.90 (+1.46), CNDO: 3.85 (+0.31), CONN: 30.28 (+1.61), DANG: 9.55 (+1.17), SMTX: 1.48 (+0.21), CBMG: 31.46 (-5.49), MRVC: 7.35 (+0.33), AMCO: 1.14 (-0.16), MOV: 28.52 (+2.89)
Great Basin Sci awarded patent covering molecular test method; shares up 53%
Seeking Alpha - at Seeking Alpha - Tue Mar 31, 11:00AM CDT
GBSN: 3.90 (+1.46)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Tue Mar 31, 8:13AM CDT
GV: 1.94 (-0.65), CANF: 2.23 (+0.03), SNTA: 1.94 (-0.39), BCRX: 9.03 (+0.46), GBSN: 3.90 (+1.46), TCK: 13.73 (-1.54), CHTR: 193.11 (+9.72), DANG: 9.55 (+1.17), CLDN: 18.94 (-2.73), REXX: 3.72 (-0.13), MOV: 28.52 (+2.89)
Great Basin Receives Patents for Company's Sample-to-Result Molecular Diagnostic Testing Technology
PR Newswire - Tue Mar 31, 7:00AM CDT
Great Basin Scientific, Inc. (NASDAQ: GBSN and GBSNU), a molecular diagnostics company, today announced that the United States Patent and Trademark Office (USPTO) issued a notice of allowance for patent 8,936,921 for the Company's method of isothermal helicase-dependent amplification (HDA) using blocked primers (bp), or "bpHDA." bpHDA creates a highly specific "hot-start" functionality which increases the amplification speed, improves assay sensitivity and expands multiplex capabilities of Great Basin's sample-to-result molecular diagnostic testing technology. bpHDA is the basis of the Company's Clostridium difficile (C. diff) molecular diagnostic test assay.
GBSN: 3.90 (+1.46), GBSNU: 13.40 (+2.65)
Great Basin Scientific up almost 50% in early trading
Seeking Alpha - at Seeking Alpha - Fri Mar 27, 9:16AM CDT
GBSN: 3.90 (+1.46)
Great Basin Schedules Conference Call to Provide Update on Corporate Progress
PR Newswire - Mon Mar 16, 3:41PM CDT
Great Basin Scientific, Inc. (NASDAQ: GBSN and GBSNU), a molecular diagnostics company, announced today it will host a management presentation on Wednesday, March 18, 2015 at 4:30 p.m. Eastern Time, to provide an update on Great Basin's progress and development programs.
GBSN: 3.90 (+1.46), GBSNU: 13.40 (+2.65)
Great Basin Scientific, Inc. Announces Initial Closing of Public Offering
PR Newswire - Tue Mar 03, 7:00AM CST
Great Basin Scientific, Inc., (NASDAQ: GBSN and GBSNU), announced today that it has completed an initial closing of a follow-on offering with respect to 2,551,965 units (out of a maximum offering of 2,724,000 units) at $8.80 per Unit for gross proceeds of $22.5 million and net proceeds of $20.5 million. Each unit consists of one share of Series E preferred stock and eight Series C warrants. Each share of Series E preferred stock will be convertible into four shares of common stock and each Series C warrant will be exercisable into one share of common stock at an exercise price of $2.55 per share. The Units will automatically separate into the Series E preferred stock and Series C warrants on August 25, 2015, provided that the Units will separate earlier if at any time after March 27, 2015 the closing price of Great Basin's common stock is greater than $4.00 per share for 20 consecutive trading days. The Units will begin trading on The Nasdaq Capital Market under the ticker symbol "GBSNU" beginning March 3, 2015.
GBSN: 3.90 (+1.46), GBSNU: 13.40 (+2.65)
Great Basin Scientific ups revenues 100% in FY14
Seeking Alpha - at Seeking Alpha - Wed Feb 18, 8:48AM CST
GBSN: 3.90 (+1.46)
Great Basin Scientific reports Q4 results
Seeking Alpha - at Seeking Alpha - Wed Feb 18, 7:36AM CST
GBSN: 3.90 (+1.46)
Great Basin Scientific Announces Fourth Quarter 2014 and Full Year 2014 Financial Results
PR Newswire - Wed Feb 18, 7:00AM CST
Great Basin Scientific, Inc. (NASDAQ: GBSN), a molecular diagnostics company, today reported financial results for the fourth quarter and the full year ended December 31, 2014. For the fourth quarter of 2014, revenue was $445,283, an increase of 50.5% compared to $295,785 for the fourth quarter of 2013. For the 12 months ended December 31, 2014 revenue was $1,606,254, an increase of 111.2% compared to $760,646 for the 12 months ended December 31, 2013.
GBSN: 3.90 (+1.46)
Great Basin begins clinical trial for Shiga toxin-producing E. coli & serotype E. coli O157:H7
M2 - Fri Feb 13, 6:31AM CST
Molecular diagnostics company Great Basin Scientific (NasdaqCM:GBSN) reported on Thursday the start of a clinical trial for its Shiga toxin-producing E. coli (STEC) diagnostic test.
GBSN: 3.90 (+1.46)
Great Basin Initiates Clinical Trial for Shiga Toxin-Producing E. coli Molecular Diagnostic Test
PR Newswire - Thu Feb 12, 7:30AM CST
Great Basin Scientific, Inc. (NASDAQ: GBSN), today announced it has initiated a clinical trial for its Shiga toxin-producing E. coli (STEC) diagnostic test. The Great Basin STEC diagnostic test will also detect serotype E. coli O157:H7.
GBSN: 3.90 (+1.46)
13 IPOs You Wish You Didn't Buy in 2014 (And Killed Your Portfolio)
at The Street - Fri Feb 06, 11:55AM CST
Here are the 13 worst performing IPO stocks in 2014.
ROKA: 3.20 (+0.07), SHAK: 50.05 (+0.43), BRDR: 6.01 (-0.14), ECR: 5.62 (+0.10), BIOC: 2.24 (-0.10), ATEN: 4.33 (+0.04), CRCM: 7.58 (-0.20), AMDA: 0.35 (-0.05), MOLG: 2.29 (+0.06), SGNL: 2.15 (-0.11), GBSN: 3.90 (+1.46), FMSA: 7.24 (+0.05), HELI: 1.33 (+0.08), REPH: 9.07 (+0.03)
Great Basin CEO, Ryan Ashton, to Present at OneMedForum 2015
PR Newswire - Thu Jan 08, 7:30AM CST
Ryan Ashton, co-founder and CEO of Great Basin Scientific, Inc. (NASDAQ: GBSN), a molecular diagnostics company, will speak at 2:20 p.m. PST, Jan. 13, at the 8th Annual OneMedForum 2015 at the Marriott Marquis Hotel in San Francisco. Management will also be available for investor meetings on Jan. 13.
GBSN: 3.90 (+1.46)
Great Basin Appoints New Board Members
PR Newswire - Tue Dec 16, 7:30AM CST
Great Basin Scientific, Inc. (NASDAQ: GBSN), a molecular diagnostics company, today welcomed Ronald K. Labrum and Sam Chawla to its board of directors. The two directors joined the board on Oct. 9 (concurrent with the Company's Initial Public Offering), expanding the size of the Great Basin's board of directors from three to five. Both Mr. Labrum and Mr. Chawla will serve as independent directors at Great Basin Scientific, Inc.
GBSN: 3.90 (+1.46)
Great Basin Schedules Product Roadmap Update Call and Webcast
PR Newswire - Thu Dec 11, 4:29PM CST
Great Basin Scientific, Inc. (NASDAQ: GBSN), a molecular diagnostics company, announced today it will host a management presentation on Wednesday, December 17, 2014 at 4:15 p.m. Eastern Time, to discuss progress on the Company's roadmap.
GBSN: 3.90 (+1.46)
